Renal

Open Clinical Trials

Nivolumab, Cabozantinib, Ipilimumab

Protocol Number: USOR 17-059
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma.